Century Therapeutics, Inc. · NASDAQ:IPSC
Century Therapeutics — Corporate Update (March 2025)
35 slides from Century Therapeutics's corporate update, Mar 19, 2025
Slide 1: Century Therapeutics
\« ) CENTURY J THERAPEUTICS D Mar 2025
Slide 2: Forward-looking statements
2 Forward - looking statements This presentation contains forward - looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this presentation, other than statements of historical f
Slide 3: Extending cash runway into 4Q26; re-allocating resources to enable key value milestones
Extending cash runway into 4Q26; re - allocating resources to enable key value milestones Enhanced preclinical pipeline and platform aiming to expand and multiply cell therapy value • Four potentially transformative programs engineered with industry - leading Allo - Evasion 5.0 • Leading programs fo
Slide 4: Clear differentiation from other allogeneic cell therapies with pathway to antibody-like scale
4 Clear differentiation from other allogeneic cell therapies with pathway to antibody - like scale Century’s ability to create multiple iPSC - derived cell types incorporating Allo - Evasion stands apart from other allogeneic cell therapy approaches Engineerability • Control of differentiation to mu
Slide 5: Allo-Evasion engineering aims to drive durable responses by enabling repeat dosing
5 Allo - Evasion engineering aims to drive durable responses by enabling repeat dosing for tighter control over drug exposure Clinical data from CNTY - 101 in ELiPSE - 1 show persistent exposure in the presence of an intact immune system 1 With Allo - Evasion engineering Without Allo - Evasion engin
Slide 6: Continued evolution to enhance holistic protection from major immunity pathways
6 Continued evolution to enhance holistic protection from major immunity pathways Century is a leader in immune evasion engineering Allo - Evasion 1.0 Deletion of HLA - I Deletion of HLA - II Insertion of HLA - E Protection from: Native T - cells Native NK - cells Humoral immunity CNTY - 101 1. Comp
Slide 7: The CD300a TASR ligand mimics natural signaling to provide broad protection from host NK cells
7 The CD300a TASR ligand mimics natural signaling to provide broad protection from host NK cells CD300a detects disordered membrane lipids TASR mimics signaling of dead or dying cells Drug Product (live) Inhibit NK Cell TASR CD300a Dead/dying c ell NK Cell Inhibit CD300a Male Female <50 >50 Gender A
Slide 8: Century is advancing a focused iPSC pipeline across cell types and targets
8 Clinical IND - enabling Research Indications Targets Product Phase 3 Phase 2 Phase 1 B - cell - mediated autoimmune diseases CD19 CNTY - 101 iNK ( Allo - Evasion 1.0) B - cell - mediated autoimmune diseases CD19 CNTY - 308 αβ iT ( Allo - Evasion 5.0) B - cell malignancies B - cell malignancies CD1
Slide 9: CAR-iNK cell therapy with Allo-Evasion 1.0
CNTY - 101 CAR - iNK cell therapy with Allo - Evasion 1.0
Slide 10: CNTY-101 currently in Phase 1 in autoimmune disorders
10 Currently in Phase 1 in autoimmune disorders https://www.centurytx.com/wp - content/uploads/ASGCT24 - CNTY - 101 - AI - Poster.pdf CNTY - 101: A CD19 - targeted CAR - iNK product candidate designed to provide precise control of drug exposure and enable repeat dosing CNTY - 101 off - the - shelf C
Slide 11: Autoimmune disorders present significant unmet medical need
11 Autoimmune disorders present significant unmet medical need Diffuse cutaneous Systemic Sclerosis (dcSSc) Idiopathic Inflammatory Myopathy (IIM) Lupus Nephritis (LN) Systemic Lupus Erythematosus (SLE) Fibrosis and vasculopathy of the skin and internal organs, with high risk for disability, disfigu
Slide 12: Clear opportunity for allogeneic cell therapies in autoimmune indications
12 Clear opportunity for allogeneic cell therapies to address moderate to severe autoimmune indications by providing long - term, drug - free remission Significant patient population and unmet need • Tens of thousands of patients with unmet need in the US • Heterogeneous nature of patients with auto
Slide 13: CNTY-101 is a differentiated autoimmune disease treatment
13 Allogeneic iPSC • Available ‘off - the - shelf ’ • No patient apheresis required • No manufacturing wait time • Batch - to - batch consistency • Platform enables lower COGs than donor - derived or autologous NK cells • Killing potency (≥ primary CAR - T) leads to deep B - cell depletion 1 • Traff
Slide 14: In vitro studies show CNTY-101 eliminates B cells with greater potency than primary CAR-T cells
14 In vitro studies show that CNTY - 101 eliminates B cells with greater potency than primary CAR - T cells https://www.centurytx.com/wp - content/uploads/ASH_Chin_Natural - Killer - GD - Cells - Final.pdf Isolated B cells or CD19+ target cells were co - cultured with CNTY - 101 or primary CAR - T a
Slide 15: CALiPSO-1 is a Phase 1 study of CNTY-101 in refractory B cell-mediated autoimmune diseases
15 CALiPSO - 1 is a Phase 1 study of CNTY - 101 in refractory B cell - mediated autoimmune diseases (NCT06255028) infusions in outpatient setting Inclusion: • Participants with moderate to severe SLE , LN, IIM, or dcSSc with treatment - resistant and active disease, after 2+ standard immunosuppressi
Slide 16: ELiPSE-1 first-in-human study: initial clinical experience in relapsed/refractory B-cell lymphoma
16 CNTY - 101 ELiPSE - 1 first - in - human study: Initial clinical experience in relapsed/refractory B - cell lymphoma validates Century’s IPSC platform Heavily pre - treated patient population (n=23 safety; n=22 efficacy) • Median 4 prior lines (range 2 - 6); 48% (11/23) of patients received prior
Slide 17: ELiPSE-1 is a dose-escalating Phase 1 study of CNTY-101 in B-cell malignancies
17 1. Standard lymphodepletion regimen: Fludarabine (30 mg/c/d) and cyclophosphamide IV (300 mg/m/d) for 3 days 2. Subjects who are assessed as stable disease or better may receive additional cycles of CNTY - 101 3. Subjects at DL4A did not receive IL - 2 on the day of CNTY - 101 infusion but di
Slide 18: CNTY-101 exposure increased with dose, sustained exposure at doses intended for CALiPSO-1
18 Source: Company data available as of March 7, 2025 CNTY - 101 exposure increased with dose, sustained exposure at doses intended for CALiPSO - 1 study Error bars show mean ± SD on original scale, subsequently log10 transformed. Due to log scale, low values are truncated at 1. All schedule B LDC+
Slide 19: Similar CNTY-101 exposure in the presence or absence of endogenous lymphocytes
19 Infusion LDC • Lymphodepleting Chemotherapy (LDC) depleted patient NK/T cell counts and drove a transient spike of IL - 15 cytokine • By post - infusion day 8, NK/T cell counts, IL - 15 concentration returned to screening level • Similar PK profile observed for each CNTY - 101 infusion within a c
Slide 20: CNTY-101 cells detected in lymph node tumor biopsies
20 Source: Company data as of March 7, 2025 CNTY - 101 cells were detected in lymph node tumor biopsies early post - treatment in Dose Level 3B and 4B CNTY - 101 iNK cells traffic to lymph nodes, observed more frequently at higher doses CAR TNFA IFNG CAR TNFA IFNG CAR CAR Day 10 Baseline CAR TNFA IF
Slide 21: CNTY-101 treatment demonstrated deep B-cell depletion
21 CNTY - 101 treatment demonstrated deep B - cell depletion and was associated with naive non - class switched profile of re - emergent B - cells Data in r/r NHL patients supports the application of CNTY - 101 in autoimmune diseases B - cell depletion Re - emergent B - cell profile • Rapid and effe
Slide 22: CNTY-CAR αβ-iT cell with Allo-Evasion 5.0
CNTY - 308 CAR αβ - iT cell with Allo - Evasion 5.0
Slide 23: CNTY-308 is an iPSC-derived CD19-targeted CAR-iT
23 CNTY - 308 is an iPSC - derived CD19 - targeted CAR - iT with preclinical efficacy comparable to autologous CD19 CAR - T cells 1. https://www.centurytx.com/wp - content/uploads/ASH_Heinze_iPSC - Derived - CD4 - CD8 - Final.pdf 2. Company data on file CD4+/CD8+ αβ iT - cell • CD19 - targeted CAR t
Slide 24: Process designed to control the ratio of CD4+ to CD8+
24 https://www.centurytx.com/wp - content/uploads/ASH_Heinze_iPSC - Derived - CD4 - CD8 - Final.pdf Century’s process is designed to control the ratio of CD4+ to CD8+ while expanding differentiating engineered CAR iPSC cells to αβ CAR - T cells Ending Viability Expansion from iPSCs ( - fold) Stage 9
Slide 25: Preclinical studies show αβ iPS-CAR-T cells similar to primary CAR-T cells
25 CNTY - 308 1’ CAR - T Function ~2,000 ~3,000 IL - 2 secretion (pg/mL) No No Requires exogenous IL - 2/IL - 15 > 10 > 10 Repeat killing (rounds) 32 32 Persistence in blood (days) Yes Yes Tumor control after rechallenge ( in vivo) CNTY - 308 and 1’ CAR - T • Self - supports with own target - mediat
Slide 26: iPSC-CAR-αβ T cells display functional characteristics of adult primary T cells
26 Century’s iPSC - CAR - αβ T cells display the functional characteristics of adult primary T cells: In vitro activity Effective T cell therapies require the generation of iPSC - CAR - T cells with three key in vitro cell functions Cytotoxicity: Effector function Cell expansion and persistence Ther
Slide 27: In preclinical animal studies, iPSC-CAR-T cells showed comparable activity to primary CAR-T cells
27 1e+06 1e+07 1e+08 1e+09 1e+10 0 10 20 30 40 Days Post−Effector Infusion L u m i n e s c e n c e ( l o g a x i s ) Group PBS only 1' CAR−T iPS−CAR−T Group 1: PBS only Group 2: 1' CAR−T Group 3: iPS−CAR−T 0 10 20 30 0 10 20 30 0 10 20 30 1e+07 1e+09 1e+11 Days Post−Effector Infusion L u m i n e s c
Slide 28: Early-stage programs target best-in-class profiles in oncology
28 Century’s early - stage programs target best - in - class profiles in oncology 1. Majzner and Mackall. Cancer Discovery. 2018. • αβ CAR - iT cells • Dual - targeting CD19 and CD22 to reduce potential for resistance in malignancy setting • Loss of CD19 in B cell malignancies treated by CD19 CAR T
Slide 29: Platform: iPSC cell foundry
Platform: iPSC cell foundry
Slide 30: Robust pre-clinical pipeline to address barriers confronting cellular therapies
30 Century’s robust pre - clinical pipeline has potential to address critical barriers confronting cellular therapies Multiple iPSC - derived immune effector cells iPSC - enabled engineering solutions Opportunity across multiple diseases • Cytokine engineering to reduce or eliminate lymphodeplet
Slide 31: Capability to make multiple cell types enables matching to indication
31 Potential for long - lived memory , mediating immune surveillance GvHD risk, eliminated by knockout of T cell receptor (TCR) Greatest proliferative potential – potentially most useful for ongoing antigenic pressure Adaptive lymphocytes – capable of generating distinct functional attributes Traffi
Slide 32: Precision CRISPR MAD7-mediated sequential gene editing of iPSCs
32 Precision CRISPR MAD7 - mediated sequential gene editing of iPSCs generates uniform product candidates Multiple gene edits (KO/KI) iPSC Engineered iPSC Master C ell Bank (MCB) Sequential selection steps iPSC Precision Engineering CRISPR - mediated HDR (MAD 7) Advantages of Century’s Platform Prec
Slide 33: Century platform and in-house manufacturing: pathway to scalable, profitable cell therapy
33 Century platform and in - house manufacturing: Pathway to scalable, profitable cell therapy Quality product at disruptive scale and cost of goods Established in - house manufacturing from development to launch • Consistency : Control of manufacturing and single - donor master - cell - bank over p
Slide 34: Extending cash runway into 4Q26; re-allocating resources to enable key value milestones
Extending cash runway into 4Q26; re - allocating resources to enable key value milestones Enhanced preclinical pipeline and platform aiming to expand and multiply cell therapy value • Four potentially transformative programs engineered with industry - leading Allo - Evasion 5.0 • Leading programs fo
Slide 35: Century Therapeutics
\« ) CENTURY J THERAPEUTICS D